ArborGen Announces Strategic Review

To: NZX From: Sharon Ludher-Chandra


Further information on ArborGen Holdings Limited can be viewed at our web site http://www.arborgenholdings.com.


ArborGen Announces Strategic Review
30 June 2021 - Global advanced genetics seedling company, ArborGen Holdings Limited (NZX:ARB)
(ArborGen or the Company) advises that the Company has received a confidential, non‐binding,
indicative, incomplete and highly conditional proposal from a credible third party to acquire all of the
shares in, or assets of, ArborGen by way of a scheme of arrangement or other alternative acquisition
structure (the Proposal). A sub-committee of independent directors of ArborGen was appointed to
assess the Proposal (the Sub-Committee) and has concluded that, based on the information currently
before the Sub-Committee, the Proposal materially undervalues the Company. In light of this, the
Board has decided to commence a strategic review. The objective of the strategic review is to consider
all options to unlock value for the benefit of all shareholders. These options could include (but are
not limited to) a potential sale of all of the shares in, or all or some of the assets of the Company, or a
US listing.
ArborGen is the largest commercial global seedling supplier and a leading provider of advanced
genetics, for the forest industry. Employing state-of-the-art technology, ArborGen is developing high-
value products that significantly improve the productivity of a given acre of land by enabling our
customers to grow trees that yield more wood per acre with greater consistency and quality in a
shorter period of time.
It specialises in loblolly pine (US and Brazil), radiata pine (New Zealand and Australia) and eucalyptus
(Brazil and Australia) plantation forestry species. It has 18 seedling nurseries, 12 seed producing
orchards and overall production capacity of 540 million seedlings annually globally.
As set out in the 27 May 2021 market announcement
(https://www.nzx.com/announcements/372976), ArborGen’s 2021 financial results outlined a
significantly improved outlook for the company driven primarily by increased availability of its
proprietary MCP seedlings in the US.
With increased availability of proprietary advanced genetic products (MCP seedlings) in the US,
improving markets in all regions, and increased demand for proprietary genetics, ArborGen believes
that it is now well positioned for accelerated growth.
PwC has been engaged to assist ArborGen in undertaking the strategic review.
There is no certainty that any transaction or other change will result from the strategic review.
ENDS
Any enquiries should be directed to:
Sharon Ludher-Chandra
Company Secretary & Performance Improvement Director (NZ-based)
E: info@arborgenholdings.com